Jordi Bertrán-Alamillo

The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj et al. · Clinical Cancer Research · 2014 · 228 citations · Full text

Medicine, Oncology, Pharmacology +15

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Amaya Gascó et al. · Clinical Cancer Research · 2014 · 198 citations

Medicine, Genetics, Oncology +15

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Kirstine Jacobsen, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila et al. · Nature Communications · 2017 · 183 citations · Full text

Medicine, Oncology, Pharmacology +17

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Jordi Bertrán-Alamillo, Valérie Cattan, Marie Schoumacher et al. · Nature Communications · 2019 · 148 citations · Full text

Medicine, Molecular Biology, Oncology +17

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions

Clara Mayo‐de‐las‐Casas, Núria Jordana‐Ariza, Mónica Garzón‐Ibáñez et al. · Annals of Oncology · 2017 · 98 citations · Full text

Medicine, Genetics, Oncology +13